Summit Therapeutics (SMMT) news
Recent news
PLC Resources Ltd - Geo-spectral survey commences at Abbotts Gold project, WA
PLC Resources Ltd (ASX: PLC) has announced the commencement of a geo-spectral survey at its Abbotts Gold project in Western Australia. The survey is part of the company’s ongoing exploration efforts to identify potential gold-bearing structures within the project area. Geo-spectral surveys utilise…
AInvest Wire · 1d agoSummit Therapeutics announces clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab in combination with trop2-directed ADC Datroway
Summit Therapeutics has announced a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate the combination of ivonescimab with a Trop2-directed antibody-drug conjugate (ADC) known as Datroway. The collaboration aims to assess the safety and efficacy of this combination therapy…
AInvest Wire · Oct 2, 2026Summit Therapeutics Inc.: Barclays raises target price to $20 from $18
Barclays has raised its target price for Summit Therapeutics Inc. (SMMT) to $20 from $18, reflecting a positive reassessment of the company’s outlook. This adjustment comes amid ongoing analyst activity across the biopharmaceutical sector, where several firms have seen recent revisions to their…
AInvest Wire · Oct 1, 2026Summit Therapeutics Junps 23%, most intraday since April 2025
On Monday, Summit Therapeutics (SMMT) experienced a significant intraday price movement, rising 23% to $19.45, marking largest single-day gain since April 2025 . The sharp increase followed the release of new clinical data related to the company’s pipeline, which generated renewed investor interest…
AInvest Wire · Sep 29, 2026Summit Therapeutics Inc.: Leerink partners raises target price to $13 from $11
Leerink Partners has upgraded its rating for Summit Therapeutics Inc. (NASDAQ:SMMT) and raised its price target to $13 from $11, according to a recent report. This adjustment reflects a shift from an "underperform" rating to "market perform," signaling a more favorable outlook for the biotechnology…
AInvest Wire · Sep 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.